Alphabet’s AI unit Isomorphic inks drug discovery deals with Eli Lilly, Novartis for up to $3B

Isomorphic Labs, Alphabet’s closely watched AI startup, has signed its first pharma partnerships, and will work with Eli Lilly and Novartis in deals that could be worth $3 billion, CEO Demis Hassabis exclusively told Endpoints News.

Since its founding in November 2021, Isomorphic has quickly become a leading figure in…
Click here to view original post